Nurix Therapeutics Inc.

NRIX | NASDAQ

Price Alert Chart Builder DCF Calculator

$25.41

-$0.03 (-0.12%)

At close: Sep 21, 2026, 4:00 PM ET

$25.40

-$0.01 (-0.04%)

Pre-market: Sep 22, 2026, 5:28 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Market Data

Market Cap $2.64B

Enterprise Value $2.25B

Beta 1.80

Average Volume 1.74M

Shares Outstanding (Diluted) 111.08M

Shares Change YoY 32.43%

Institutional Ownership N/A

Exchange NASDAQ

ISIN US67080M1036

Price Performance

Price Change 1M -3.6%

Price Change 3M 34.7%

Price Change 6M 64.6%

Price Change YTD 40.7%

Price Change 1Y 201.4%

Price Change 3Y 187.1%

Price Change 5Y -22.6%

1M CAGR (ann.) 0.9%

1Y CAGR (ann.) 196.8%

5Y CAGR (ann.) -6.6%

All-Time CAGR 4.8%

Valuation

PE Ratio -7.37

Forward PE N/A

PEG Ratio 0.28

Forward PEG 0.27

PS Ratio 71.73

Forward PS 23.00

PB Ratio 6.55

P/FCF Ratio -8.66

P/Adj. FCF Ratio -7.66

P/OCF Ratio -9.62

EV/Sales 61.24

EV/EBIT -6.59

EV/EBITDA -6.96

EV/FCF -7.39

Earnings Yield -13.6%

FCF Yield -11.6%

Adj. FCF Yield -13.1%

Financial Health

Net Cash $443.53M

Total Debt $58.14M

Cash & Short-Term Investments $443.53M

Total Assets $535.54M

Current Ratio 6.34

Quick Ratio 6.34

Debt / Equity Ratio 0.14

Debt / EBITDA -0.18

Debt / FCF -0.19

OCF / Debt -5.05

Interest Coverage 0.00

Altman Z-Score 7.66

Piotroski F-Score 2

Margins & Profitability

Gross Profit Margin -165.5%

Operating Profit Margin -982.4%

EBITDA Margin -869.6%

Net Profit Margin -928.4%

FCF Margin -828.3%

Adj. FCF Margin -936.1%

SBC / Revenue 107.8%

SBC Impact (per share) -13.0%

Returns

Return on Assets -63.7%

Return on Equity -76.1%

Return on Invested Capital -77.3%

Return on Capital Employed -77.9%

Return on Tangible Assets -63.7%

Historical Growth (CAGR)

Revenue CAGR 3Y -15.5%

Revenue CAGR 5Y 9.9%

Revenue CAGR 10Y N/A

EPS CAGR 3Y -8.8%

EPS CAGR 5Y 0.3%

EPS CAGR 10Y N/A

FCF CAGR 3Y -46.8%

FCF CAGR 5Y -20.4%

FCF CAGR 10Y N/A

Analyst Forecasts

Analyst Rating Buy

Analyst Count 19

EPS Growth Next 3Y 21.6%

Revenue Growth Next 3Y 89.1%

Earnings Date N/A

EPS Estimate (next Q) N/A

EPS Growth Est (next Q) N/A

Revenue Est (next Q) N/A

Revenue Growth Est (next Q) N/A

Fair Value Estimates

Graham Number N/A

Graham Upside N/A

Lynch Fair Value N/A

Lynch Upside N/A

Price Target $34.67

Price Target Upside 36.4%

Cash Flow

Operating Cash Flow $-293.7M

Free Cash Flow $-304.53M

Adj. Free Cash Flow $-344.18M

FCF Per Share -$2.74

OCF Per Share -$2.64

OCF/S Ratio -798.8%

Income Statement

Revenue $36.77M

Gross Profit $-57M

Operating Income $-361.18M

EBITDA $-323.58M

Net Income $-341.35M

EPS (Diluted) -$3.45

Revenue / Employee $115.98K

Profit / Employee $-1.08M

Employees 317